A March filing by Salix revealed that Allergan made a $13 billion offer for it that was eventually withdrawn. The deal broke off after Allergan apparently discovered accounting errors during its due diligence review of Salix. Actavis emerged as a prospective buyer of Allergan a short while later, taking that deal in another direction. Valeant and Ackman soon threw in the towel on their pursuit of Allergan and went shopping for another target, continuing their roll-up strategy with an eye on Salix. It turned out that Valeant got some benefit from Allergan's earlier due diligence on Salix, too—it struck a deal to buy the Raleigh-based company for $11.1 billion, 18% lower than Allergan's last offer. Allergan, Actavis and Pyott are not directly referred to in Salix' filing, but there are references throughout the document that offer enough in the way of descriptions to identify "Company A" as Allergan and "Company B" as Actavis. The filing shows that Allergan and Salix had been in communication since November 2013.